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Background: Although patients have different treatment preferences, these individual
preferences could often be grouped in subgroups with shared preferences. Knowledge of
these subgroups as well as factors associated with subgroup membership supports health care
professionals in the understanding of what matters to patients in clinical decision-making.
Objectives: To identify subgroups of patients with rheumatoid arthritis (RA) based on their
shared preferences toward disease-modifying antirheumatic drugs (DMARDs), and to iden-
tify factors associated with subgroup membership.
Methods: A discrete choice experiment to determine DMARD preferences of adult patients
with RAwas designed based on a literature review, expert recommendations, and focus groups.
In this multicenter study, patients were asked to state their preferred choice between two different
hypothetical treatment options, described by seven DMARD characteristics with three levels
within each characteristic. Latent class analyses and multinomial logistic regressions were used
to identify subgroups and the characteristics (patient characteristics, disease-related variables,
and beliefs about medicines) associated with subgroup membership.
Results: Among 325 participating patients with RA, three subgroups were identiﬁed: an
administration-driven subgroup (45.6%), a beneﬁt-driven subgroup (29.7%), and a balanced
subgroup (24.7%). Patients who were currently using biologic DMARDs were signiﬁcantly
more likely to belong to the balanced subgroup than the administration-driven subgroup (relative
risk ratio (RRR): 0.50, 95% CI: 0.28–0.89). Highly educated patients were signiﬁcantly more
likely to belong to the beneﬁt-driven subgroup than the balanced subgroup (RRR: 11.4, 95% CI:
0.97–133.6). Patients’ medication-related concerns did not contribute signiﬁcantly to subgroup
membership, whereas a near-signiﬁcant association was found between patients’ beliefs about
medication necessity and their membership of the beneﬁt-driven subgroup (RRR: 1.12, 95% CI:
1.00–1.23).
Conclusion: Three subgroups with shared preferences were identiﬁed. Only biologic
DMARD use and educational level were associated with subgroup membership.
Integrating patient’s medication preferences in pharmacotherapy decisions may improve
the quality of decisions and possibly medication adherence.
Keywords: rheumatoid arthritis, disease-modifying antirheumatic drugs, discrete choice
experiment, treatment preferences
Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease characterized by synovial
inﬂammation, which can lead to irreversible articular damage, a decrease in physical
functioning, and radiologic progression.1–3 Patients are recommended to use
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disease-modifying antirheumatic drugs (DMARDs) to sup-
press the inﬂammatory response and to improve clinical
outcomes.1,3 Nevertheless, non-adherence to these drugs is
a major issue. Depending on the measurement method used,
adherence rates to DMARDs vary from 58% to 92%.4–6 Low
adherence rates contribute to increased disease activity, the
impairment of physical functioning and quality of life, struc-
tural damage to cartilage and bone, and high individual and
societal costs.1,4 In recent years, tailoring treatment to
patients’ medication preferences has gained increased atten-
tion as a promising strategy to improve medication
adherence.1,7,8
Conventional and targeted DMARDs have different
characteristics, providing the opportunity to ﬁt treatment
options to patient’s medication preferences. Each
DMARD consists of a set of characteristics (ie, attributes,
for instance route of administration) with multiple levels
(eg, oral, subcutaneous, and intravenous within the attribute
“route of administration”). These attributes and levels
enable patients to make trade-offs regarding treatment ben-
eﬁts and drawbacks.9 Integrating patient’s medication pre-
ferences in treatment decisions is essential, since patient
preferences are not always in line with treatment protocols
or the preferences of rheumatologists.10 Misalignment
between patient’s and rheumatologist’s preferences or treat-
ment protocols might result in non-adherence to medica-
tion. Thus, prescribers should take patient preferences into
account to increase decision quality and possibly medica-
tion adherence.
It has previously been shown that patient’s beliefs
about a speciﬁc medicine (ie, necessity beliefs and concern
beliefs about the prescribed treatment) are associated with
treatment preferences and adherence to medication.11–13
The association between subgroups with shared DMARD
preferences and patient-related characteristics (including
necessity and concern beliefs) in rheumatic diseases is,
however, understudied. Only one previous study investi-
gated the contribution of beliefs about medicines to treat-
ment preferences in patients with RA, but the researchers
disregarded the possible existence of subgroups with simi-
lar preference patterns within patients with RA.14 Insight
in meaningful subgroups as well as patient characteristics
(eg, demographic, clinical, and psychological determi-
nants) associated with these subgroups might support
health care professionals in the understanding of what
matters to patients in clinical decision-making. These
insights allow further optimization of patient-tailored deci-
sions regarding DMARD treatment by applying these
insights in, eg, communication strategies, communication
styles, and patient education.
The primary objective of this study is therefore to elicit
the preferences of patients with RA regarding DMARD
characteristics, and to identify subgroups with shared pre-
ferences. The secondary objective is to study different
patient characteristics, including beliefs about medicines,
which may be associated with these subgroups.
Patients and methods
Study design and setting
This cross-sectional multicenter study was performed in
collaboration with ﬁve rheumatology departments across
the Netherlands: Sint Maartenskliniek, Reade, Erasmus
MC, Medisch Spectrum Twente, and Maastricht UMC+.
A discrete choice experiment (DCE), implemented in an
online survey, was used to elicit patient preferences toward
DMARDs. The survey was conducted between April 12,
2017 and November 30, 2017. The STROBE statement for
cross-sectional studies provided guidance for the adequate
reporting of this study.15
Eligibility criteria and patient recruitment
The eligibility criteria for patients participating in this
study were: 1) clinical diagnosis of RA by
a rheumatologist, 2) current user of at least one DMARD
according to their medical ﬁle, 3) aged ≥18 years, and 4)
proﬁciency of the Dutch language. All patients were
approached in collaboration with their treating clinician
and the medical head of the department. One to three
weeks before their regular outpatient visit, an information
letter and informed consent form were sent to all eligible
patients. After receiving a patient’s written informed con-
sent, the researcher contacted the patient by email or tele-
phone to send a web link to complete the online survey at
home or to schedule a research appointment at the study
site, respectively.
Procedures of data collection
If patients chose the option to complete the survey at home
but did not complete it within one week, a reminder was
sent by email. If patients completed the survey more than
once, they were contacted by telephone to ask which set of
answers best represented their preferences, and to explore
the reasons for duplicates.
As part of the online survey, patients were asked about
their preferences toward DMARDs, demographics (age,
van Heuckelum et al Dovepress
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gender, nationality, employment status, educational level,
and marital status), clinical characteristics (disease duration,
current and previous DMARD use), and medication beliefs
based on the 10-item Beliefs about Medicines Questionnaire
(BMQ)-Speciﬁc. Data were extracted from the online data-
base using Lighthouse Studio (Sawtooth Software ver-
sion 9.5.2.).
Measurement instruments
Discrete choice experiment (DCE)
The checklist developed by the ISPOR Good Research
Practices for Conjoint Analysis Task Force was used to
report the steps involved in conducting this DCE.16,17
Identiﬁcation and selection of relevant attributes and
levels
The identiﬁcation and selection process of attributes and
levels is described brieﬂy in this article. For a more
detailed description of this process, see Mathijssen et al.18
A literature search in PubMed, CINAHL, and Embase was
performed on September 27, 2016, to identify DMARD attri-
butes and levels from previous research involving patients
with RA. The following search terms, both MeSH terms and
free text words, were included in the literature search: rheu-
matoid arthritis, DMARDs, preferences, and attributes. Titles
and abstracts were screened independently by two researchers
(pairs formed between EM, MH, LvD, and MV), followed by
screening the full texts. Full texts were included if they were:
1) studies on adult (≥18 years) patients with RA; and 2) studies
on attributes of DMARDs, preferences for DMARDs, or
experiences with DMARDs. Subsequently, a group of experts
was asked to individually complement this list of attributes
and levels from the literature search. This group of experts
consisted of two rheumatologists, two rheumatology-
specialized nurses, two researchers (not members of the
research team), two pharmacists, and two patients with RA.
The recommendations from this expert panel were used to
complement the list of attributes and levels before the focus
group discussions. Three focus groups involving a total of 23
patients with RAwere held to obtain further in-depth informa-
tion and to individually rank the 22 identiﬁed attributes and
levels. Participants were also asked to complement the list
with missing attributes and their corresponding levels. The
identiﬁed attributes and levels were discussed during
a consensus meeting (attendees: BB, EM, LvD, MH, and
MV), which resulted in a ﬁnal subset of seven attributes
(each with three levels) included in the online survey (see
Table 1).
DCE design
A choice-based conjoint design, including 12 random
choice tasks and two ﬁxed dominant choice tasks, was
used for discrete choice modeling (Lighthouse Studio:
CBC, Sawtooth Software). The random tasks were used
to elicit patient preferences, whereas the ﬁxed dominant
tasks were used to measure internal validity. Examples of
a random choice task and a ﬁxed dominant choice task are
presented in Supplementary materials (Table S1 and S2
respectively). A traditional full-proﬁle choice-based con-
joint design with complete enumeration was used, provid-
ing orthogonality (all attribute levels varied independently
Table 1 List of attributes with corresponding levels used in the
ﬁnal design of the DCE. These attributes and levels were
obtained from a literature search, expert recommendations,
and three focus groups with patients with RA.
DMARD attributes DMARD levels
Route of administration Oral (tablets/capsules)
Subcutaneous (injection in
the upper leg or abdomen)
Intravenous (infusion)
Frequency of administration Monthly
Weekly
Daily
Onset of action One week
Six weeks
12 weeks
Risk of cancer (ie, skin cancer with
favorable prognostic factors)
No risk
0.1%
0.5%
Risk of liver injury (ie, higher levels
of liver damage markers)
No risk
0.1%
1.0%
Risk of serious infections (eg, hospi-
tal admissions/discontinuation of
antirheumatic drugs)
No risk
0.1%
1.0%
Chance of efﬁcacy 80%
60%
40%
Abbreviations: DCE, discrete choice experiment; DMARD, disease-modifying
antirheumatic drug; RA, rheumatoid arthritis.
Dovepress van Heuckelum et al
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across attributes), minimal overlap, and equally balanced
level combinations (each level was presented an equal
number of times within an attribute).17 A forced choice-
elicitation format without an “opt-out” or “no-treatment”
option was used due to the decision context of the experi-
ment. The complexity of the DCE choice tasks was tested
on a scale from 0 to 10 with higher scores indicating
a higher level of complexity. The online survey was pre-
tested in ﬁve patients with RA to assess response efﬁ-
ciency, including the complexity of the DCE choice
tasks, respondent fatigue, and the comprehensibility of
the online survey.17 Data collection started after pretesting.
Beliefs about medicines questionnaire speciﬁc
(BMQ-Speciﬁc)
The BMQ-Speciﬁc was used to measure patient’s necessity
beliefs and concerns about DMARDs. Each item of the
BMQ-Speciﬁc was scored from 1 (strongly disagree) to 5
(strongly agree), resulting in a summated score from 5 to 25
for each subscale (necessity and concerns). Low necessity or
concern beliefs were deﬁned as summated scale scores
<15.19 High necessity or concern beliefs were deﬁned as
summated scale scores ≥15.19 Patients were further classiﬁed
into four proﬁles according to the necessity-concerns frame-
work developed by Horne et al: accepting (high necessity,
low concerns), ambivalent (high necessity, high concerns),
indifferent (low necessity, low concerns), and skeptical (low
necessity, high concerns).11,19,20
Study size
The sample size was calculated based on the rule of thumb
(N>500c/(t×a)) proposed by Orme et al, which considers the
number of choice tasks (t), the number of alternatives (a), and
the number of analysis cells (c).21 The number of random
tasks was estimated to be 12, the number of alternatives per
task (not including the “none” alternative) was two, and the
number of analysis cells (based on the main effects) was
three, as each attribute consisted of three levels.21 Based on
these estimates, the minimum sample size for the choice-
based conjoint analysis was 63. Considering the research
question regarding the identiﬁcation of different subgroups
and the hypothesis that respondents would be divided into at
least three subgroups, a sample size of at least 200 patients
was considered appropriate for this study.21,22
Statistical methods
Statistical analyses were performed using STATA version
13.1. Descriptive statistics were used to describe the
patient and disease characteristics. Educational level
was classiﬁed in low, moderate, or high educational
level. Low educational level was deﬁned as no education,
(extended) primary education or pre-vocational educa-
tion, moderate educational level was deﬁned as voca-
tional education or selective secondary education, and
high educational level was deﬁned as education provided
by universities of applied sciences and research univer-
sities. Data were presented as means and standard devia-
tions or percentages. Incomplete surveys were excluded
from the data analysis.
Part-worth utilities were the numerical data obtained
from discrete choice modeling. Higher part-worth utili-
ties represented stronger preferences for levels within an
attribute, whereas negative utility scores were considered
less attractive. The DCE data were analyzed in a latent
class analysis to identify subgroups within the total study
sample (Analysis Manager version 9.5.2; Lighthouse
Studio, Sawtooth Software). Model ﬁt tests (Consistent
Akaike Information Criterion and Bayesian Information
Criterion) were performed to identify the number of seg-
ments in our data. The highest probability for subgroup
membership was decisive in assigning respondents to
subgroups. Each subgroup was characterized by their
shared part-worth utilities.23 In other words, patients
who displayed similar part-worth utilities (ie, preferences
toward DMARD characteristics) were categorized in the
same subgroup, whereas patients who displayed conﬂict-
ing part-worth utilities were categorized in different sub-
groups. Part-worth utilities represent the strength and
direction of preferences for DMARD characteristics
within an attribute, whereas the relative importance of
an attribute represents the importance of this attribute
relative to other attributes. The relative importance of
an individual attribute in the overall choice for
a DMARD was calculated by dividing the range of part-
worth utilities within an attribute by the sum of ranges
across attributes, multiplied by 100.
Multinomial logistic regression models (with one sub-
group as base scenario) were used to determine whether
patient characteristics, disease-related characteristics, and
beliefs about medicines were related to subgroup member-
ship. Bivariate analyses were performed to select the most
important predictors to prevent overﬁtting of the model
due to the large number of variables measured in this
study. Determinants with P-values <0.2 were entered in
the ﬁnal model. In the ﬁnal model, P-values ≤0.05 were
considered statistically signiﬁcant.
van Heuckelum et al Dovepress
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Ethical approval
The study protocol was reviewed by the Institutional
Review Board of the Sint Maartenskliniek Nijmegen and
ethical approval was obtained from the local Medical
Ethics Committees. This study was conducted according
to the ethical principles for medical research as stated in
the Declaration of Helsinki (64th WMA General
Assembly, Fortaleza, Brazil, 2013).
Results
Sample characteristics
Initially, 1,317 patients were invited to participate in this
study. Of these patients, 24.7% (N=325; range for hospitals:
18.8–28.6%) completed the survey. Figure 1 shows the ﬂow-
chart of the survey response. Patient characteristics are shown
in Table 2. On average, patients were 63.3 (SD=11.9) years
old and had a mean disease duration of 14.7 (SD=11.2) years.
Of the patients who completed the survey, 69.2% were
female, 39.7% had a low educational level, 40.0% were
(early) retired, and 20.0% were living alone. Regarding
beliefs about medicines, 52.9% of the patients were categor-
ized in the “accepting” quadrant and 39.1% comprised the
“ambivalent” quadrant. The “indifferent” and “skeptical”
quadrants were both represented by 4.0% of the patients.
Internal validity
Mean score for the complexity of the online survey was 5.3
(SD=2.2). Of all respondents, 1.5% and 2.2% gave an
irrational response (ie, stated a preference for the worst-
case scenario, eg, “Medicine 1” in Table S2) to the ﬁrst
and second ﬁxed choice task, respectively. Overall, those
respondents did not inﬂuence the results on DMARD pre-
ferences and the identiﬁcation of subgroups (data not
shown); therefore, all respondents were included for analysis.
Identiﬁcation of subgroups with similar
preferences
The latent class analysis identiﬁed three subgroups with the
following segment sizes: a beneﬁt-driven subgroup (29.7%),
a balanced subgroup (24.7%), and an administration-driven
subgroup (45.6%). See Tables S3 and S4 for the results of the
identiﬁcation process of subgroups with latent class analyses
in this study. The groups were identiﬁed with a name that
characterized the aspects they considermost important.Within
the beneﬁt-driven subgroup, the relative importance of the
attribute chance of efﬁcacy (43.6%) was highest, whereas
the relative importance of route of administration (38.2%)
was highest in the administration-driven subgroup. In contrast
with the other subgroups, the choice for a DMARD in the
balanced subgroup was more equally inﬂuenced by multiple
attributes (Figure 2); however, risk of cancer (17.0%) and
onset of action (14.5%) were relatively more important for
the balanced subgroup than for the other subgroups. Between-
group differences were smallest for the attributes frequency of
administration and risk of serious infections. The largest
between-group differences were sequentially found for the
Total number of patients invited to participate in this
study
N=1317
Number of patients
Amsterdam
N=300
Respone rate=20.3%
Number of complete
surveys
N=61
Number of complete
surveys
N=79
Number of complete
surveys
N=79
Number of complete
surveys
N=78
Total number of
complete surveys
N=325A
Number of complete
surveys
N=27
Respone rate=26.3% Respone rate=28.6% Respone rate=26.3% Respone rate=18.8%
Number of patients
Enschede
N=300
Number of patients
Maastricht
N=276
Number of patients
Nijmegen
N=297
Number of patients
Rotterdam
N=144
Figure 1 Flow chart of survey response across study sites. AStudy site was unknown for one completed survey.
Dovepress van Heuckelum et al
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attributes chance of efﬁcacy, route of administration, risk of
cancer, and onset of action (Figure 2).
Part-worth utilities of levels between and
within subgroups
The part-worth utilities of attribute levels differed between
the subgroups, revealing that members of each subgroup
made different trade-offs between DMARD characteristics
(see Figure 3). Although the direction of most part-worth
utilities within each attribute was similar for the three
subgroups, the level part-worth utilities within the attribute
route of administration were remarkably different. The
administration-driven subgroup had a strong preference
for tablets or capsules, and was less likely to prefer an
intravenously administered DMARD. The beneﬁt-driven
subgroup also preferred tablets or capsules over subcuta-
neous injections; however, these part-worth utilities were
not signiﬁcantly different. The balanced subgroup had
a strong preference for subcutaneous injections, followed
by an intravenously administered DMARD. Members of
this subgroup were less likely to prefer tablets or capsules
for DMARD administration.
Factors associated with subgroup
membership
Multinomial logistic regression (see Table S5) revealed that
patients who were currently using bDMARDs were signiﬁ-
cantly less likely to belong to the administration-driven sub-
group (with a strong preference for the oral route of
administration) than the balanced subgroup (RRR: 0.50,
95% CI: 0.28–0.89). Highly educated patients were signiﬁ-
cantly more likely to belong to the beneﬁt-driven subgroup
than the balanced subgroup (RRR: 11.4, 95% CI:
0.97–133.7). The following patient characteristics were not
Table 2 Sample characteristics.
Sample characteristics Frequency (%) or
mean (SD)
Total number of patients, N (%) 325 (100)
Patient-related factors
Age, mean (SD), years 63.3 (11.9)
Female, N (%) 225 (69.2)
Dutch nationality, N (%) 324 (99.7)
Marital status
Married, N (%) 229 (70.5)
Educational level
Low, N (%) 129 (39.7)
Moderate, N (%) 91 (28.0)
High, N (%) 103 (31.7)
Not speciﬁed, N (%) 2 (0.6)
Living status
Alone, N (%) 65 (20.0)
With partner, N (%) 245 (75.4)
With children, N (%) 11 (3.4)
Other, N (%) 4 (1.2)
Employment status
Employed, N (%) 94 (28.9)
Pensioner or early retirement, N (%) 130 (40.0)
Unemployed, N (%) 10 (3.1)
Housewife or househusband, N (%) 36 (11.1)
Disability pension/assistance, N (%) 54 (16.6)
Student, N (%) 1 (0.3)
Beliefs about medicines
Skeptical, N (%) 13 (4.0)
Indifferent, N (%) 13 (4.0)
Ambivalent, N (%) 127 (39.1)
Accepting, N (%) 172 (52.9)
BMQ subscale concerns, mean (SD) 19.2 (3.2)
BMQ subscale necessity, mean (SD) 13.9 (3.5)
Disease-related factors
Disease duration, mean (SD), years 14.7 (11.2)
Current DMARD use
Methotrexate, N (%) 207 (63.7)
Hydroxychloroquine, N (%) 64 (19.7)
Sulfasalazine, N (%) 39 (12.0)
Other cDMARD(s), N (%) 22 (6.8)
Anti-TNF, N (%) 94 (28.9)
Other bDMARD(s), N (%) 41 (12.6)
Corticosteroids, N (%) 61 (18.8)
None, N (%) 17 (5.2)
DMARD use in the past
Methotrexate, N (%) 222 (68.3)
Hydroxychloroquine, N (%) 118 (36.3)
(Continued)
Table 2 (Continued).
Sample characteristics Frequency (%) or
mean (SD)
Sulfasalazine, N (%) 87 (26.8)
Other cDMARD(s), N (%) 56 (17.2)
Anti-TNF, N (%) 102 (31.4)
Other bDMARD(s), N (%) 30 (9.2)
Corticosteroids, N (%) 140 (43.1)
None, N (%) 31 (9.5)
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; DMARD, disease-
modifying antirheumatic drug; bDMARD, biologic DMARD; cDMARD, conventional
DMARD.
van Heuckelum et al Dovepress
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signiﬁcantly associated with subgroup membership: age, sex,
employment status, study site, disease duration, current use of
corticosteroids, and bDMARD and corticosteroid use in the
past.
Patient preferences and beliefs about
medicines
Since the “indifferent” and “skeptical” quadrants are repre-
sented to a limited extent in this study, summated scale scores
for necessity and concern beliefs were used instead of the
BMQ proﬁles in the statistical analyses. Multinomial logistic
regression analyses (see Table S5) revealed that patients’
medication-related concerns did not contribute signiﬁcantly
to subgroup membership, whereas a near-signiﬁcant associa-
tion was found between patients’ beliefs about medication
necessity and their membership of the beneﬁt-driven sub-
group (RRR: 1.12, 95% CI: 1.00–1.23).
Discussion
In this study, we identiﬁed three subgroups with the fol-
lowing segment sizes based on their shared preferences
regarding DMARDs: a beneﬁt-driven subgroup (29.7%),
a balanced subgroup (24.7%), and an administration-
driven subgroup (45.6%). Patients who were currently
using bDMARDs were signiﬁcantly less likely to belong
to the administration-driven subgroup than the balanced
subgroup, which could be explained by patients’ attitude
toward or experience with subcutaneously administered
DMARDs. A high educational level was signiﬁcantly
associated with membership of the beneﬁt-driven sub-
group (base scenario: balanced subgroup). However, sig-
niﬁcant results with wide conﬁdence intervals should be
interpreted with care.
A latent class analysis to identify subgroups within the
population of patients with RA was previously reported by
Fraenkel et al, who used a ﬁve-group solution to determine the
following mutually exclusive categories/subgroups of
patients: cost-driven (38.4%), bothersome side effects
(25.8%), onset and infection (18.0%), rare side effects
(11.2%), and administration-driven (6.6%).24 The attributes
and levels included in their survey substantially differed
from the attributes and levels included in our DCE, and the
segment size of the administration-driven subgroup was much
smaller (6.6% versus 45.6% in the present study).24 These
contrary results might be explained by the differences in
national health care systems (eg, out-of-pocket costs are dif-
ferent from patient to patient in the United States and are all
covered in the Netherlands).24 Based on this, it can be con-
cluded that, if the cost perspective is less important for patients
in other settings, it is assumed that our DCE results are more
generalizable to these settings than those of Fraenkel et al.24
To our knowledge, the association between patient pre-
ferences and beliefs about medicines was only previously
described by Alten et al.14 These authors reported conﬂicting
results on the association between patient’s beliefs about
medicines and their preferences, which may be due to the
use of a modiﬁed version of the validated BMQ (ie,
Figure 2 Relative importance of attributes for each subgroup.
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adjustments in the number of items and item values).14 Alten
et al reported that all four BMQ proﬁles signiﬁcantly con-
tributed to the best-worst pairs chosen in their DCE,
whereas in our study only necessity beliefs were slightly,
but not signiﬁcantly, associated with membership of the
beneﬁt-driven subgroup.14 Differences in study setting
(including health care systems and reimbursement),
study population, DCE design, and statistical analyses of
the current and previous studies may explain the differ-
ences in results, and also make it difﬁcult to compare the
results of both studies.10,14,24–31 For this reason, the extra-
polation of DCE results to other settings or (sub)popula-
tions is not always justiﬁed. It is, however, assumed that
our results can be generalized to other settings and
-250 -200
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Figure 3 Part-worth utilities for the levels within each attribute for each subgroup, rescaled for comparability. Higher part-worth utilities represent stronger preferences for
a particular level within an attribute, whereas negative utility scores were considered less attractive.
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populations if sample characteristics, health care systems,
reimbursement, and access to medication largely corre-
spond to those in our study.
The strength of our work relies on the extensive pre-
study, which used a three-step mixed-methods approach to
identify, reﬁne, and select attributes and levels for our
DCE.18 This contributed to a more accurate DCE design
for investigating the preferences of this patient
population.18 Together with the multicenter study design
and our broad inclusion criteria, which had no restrictions
in terms of disease duration, disease activity, and current
or previous DMARD use, our results are assumed to be
more representative of the diversity of patients visiting
a rheumatologist than the strictly selected samples
recruited in previous studies.10,14,24–31 Differences in
patient recruitment (ie, nationwide panels/networks) and
study settings were also considered to limit the general-
izability of previous work.10,14,24–31 Also, in contrast with
previous research, we avoided the use of ordinal-scaled
levels due to their higher risk of heterogeneous interpreta-
tion and subjectivity. Instead, a sufﬁcient, but realistic,
contrast in levels was incorporated into the study, to
avoid discouraging patients from completing the online
survey.
Our work has also some limitations, one of which is the
possible unintended selection bias or bias due to non-
response to the information letter or questionnaire.
However, it can be assumed that the low response rate
(24.7%) will not affect the number and type of subgroups
identiﬁed in this research, since no signiﬁcant differences in
sex, age, and proportion of bDMARD use between partici-
pants and the general RA population in the Sint
Maartenskliniek were found. Due to the limited access of
data on non-participating patients across study sites, the
general RA population in the Sint Maartenskliniek was
chosen as reference as this center is one of the largest
rheumatology specialized centers in the Netherlands.
Regarding beliefs about medicines, indifferent and skepti-
cal proﬁles were underrepresented, however similar distri-
butions were found in previous studies.19,32 Patients with
low health literacy skills may also be underrepresented in
our study sample, since our DCE was implemented in an
online survey and health literacy was not measured. The
absence of clinical data (ie, due to limited access to patients’
medical ﬁles at the different study sites and differences in
measuring disease activity scores) and adherence data is
another limitation, since clinical- and adherence data may
be associated with subgroup membership and be relevant in
clinical practice. Also, remarkable were the patients who
were using a DMARD according to their medical ﬁle, but
reported no current DMARD use (5.2%) when explicitly
asked in the online survey. Most common reason for this
ﬁnding was a (temporary) discontinuation of DMARD ther-
apy (eg, due to the initiation of chemotherapy or side effects
of DMARDs) between patient selection and patient inclu-
sion. Additionally, decision-making in real-life settings
may differ from the choices made in our study, in which
respondents evaluated different treatment options within
the same choice context and in a study setting. External
factors may also inﬂuence actual choice behavior, such as
the skills of rheumatologists to motivate patients to undergo
DMARD treatment, disease ﬂares, the involvement of sig-
niﬁcant others, hospital policies, and health insurance com-
panies. Nevertheless, insights into intentional choice
behavior can form the backbone for predicting actual
behavior,33 and can support an effective communication
strategy between patients and providers by integrating
patient’s preferences into treatment decisions. This may
eventually improve medication adherence in clinical
practice.
In conclusion, three subgroups with shared DMARD
preferences were identiﬁed in patients with RA. However,
distinguishing patients based on their beliefs about medi-
cines, and patient and clinical characteristics is complex.
Rheumatologists should be aware of the existence of these
subgroups and ask patients with RA about their prefer-
ences toward DMARD characteristics to increase decision
quality, anticipate on their beliefs about medicines, and
possibly increase medication adherence. Future research
should focus on effective strategies to support rheumatol-
ogists and other clinicians in revealing DMARD prefer-
ences in real-life settings, which could eventually support
and optimize patient-tailored decisions regarding DMARD
treatment. From the patient’s perspective, the value of
a decision aid, eliciting their preferences, beliefs about
medicines, and likely medication adherence, should be
further explored.
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Supplementary material
Table S1 Example of a random choice task. Twelve random choice tasks without an “opt-out” or “no-treatment” option were
included in the discrete choice experiment.
DMARD characteristic Medicine 1 Medicine 2
Route of administration Oral (tablets/
capsules)
Subcutaneous (injection in the upper leg or
abdomen)
Frequency of administration Weekly Monthly
Onset of action Six weeks 12 weeks
Risk of cancer (eg, skin cancer with favorable prognostic factors) No risk 1 of 1,000 patients (0.1%)
Risk of liver injury (eg, higher levels of liver damage markers) 1 of 1,000 patients
(0.1%)
No risk
Risk of serious infections (eg, hospital admissions/discontinuation of anti-
rheumatic drugs)
No risk 1 of 1,000 patients (0.1%)
Chance of efﬁcacy 80% 60%
Preference for Medicine 1 or Medicine 2 □ □
Abbreviation: DMARD, disease-modifying antirheumatic drug.
Table S3 Final settings latent class analysis (Lighthouse Studio: CBC, Sawtooth Software)
Included tasks Complete ﬁeld only
Excluded tasks DCE_ﬁxed1, DCE_ﬁxed2
Minimum number of groups 2
Maximum number of groups 5
Number of replications 5
Maximum number of iterations 100
Table S2 Example of a dominant ﬁxed choice task. Two dominant ﬁxed choice tasks without an “opt-out” or “no-treatment” option
were included in the discrete choice experiment.
DMARD characteristic Medicine 1 Medicine 2
Route of administration Oral (tablets/capsules) Oral (tablets/capsules)
Frequency of administration Weekly Weekly
Onset of action 12 weeks Six weeks
Risk of cancer (eg, skin cancer with favorable prognostic factors) 1 of 1,000 patients (0.1%) No risk
Risk of liver injury (eg, elevated levels of liver damage markers) 1 of 1,000 patients (0.1%) No risk
Risk of serious infections (eg, hospital admissions/discontinuation of anti-rheumatic drugs) 1 of 100 patients (1.0%) No risk
Chance of efﬁcacy 60% 80%
Preference for Medicine 1 or Medicine 2 □ □
Abbreviation: DMARD, disease-modifying antirheumatic drug.
Table S4 Results of the identiﬁcation process of latent classes in this study
Number of latent classes Consistent Akaike Information Criterion (CAIC) Bayesian Information Criterion (BIC)
2 4265.0 4236.0
3 4257.8 4213.8
4 4357.2 4298.2
5 4406.0 4332.0
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Table S5 Adjusted multinomial logistic regression model to identify factors associated with subgroup membership. Reference
categories for categorical patient variables were: employment status (unpaid), education level (low), current bDMARD use (no),
and educational level × complexity of the online survey (low). Educational level was classiﬁed in low, moderate and high educational
level. Low educational level was deﬁned as no education, (extended) primary education or pre-vocational education, whereas high
educational level was deﬁned as education provided by universities of applied sciences and research universities
Subgroup 1 (administration-driven) Relative risk ratio (RRR) 95% conﬁdence interval P-value
Age 1.00 0.97–1.03 0.98
Employment status (paid/unpaid)a 1.13 0.52–2.42 0.76
Educational level
Moderate 0.81 0.11–5.88 0.84
High 6.97 0.72–67.5 0.09
Current bDMARD use (yes/no) 0.50 0.28–0.89 0.02**
Complexity score online survey (1–10) 0.89 0.73–1.09 0.26
Educational level × complexity of the online survey
Moderate 1.01 0.72–1.41 0.94
High 0.82 0.57–1.17 0.27
Sum score necessity beliefs 1.08 0.98–1.18 0.11
Constant 0.97 0.44–21.4 0.99
Subgroup 2 (balanced) Base outcome Base outcome Base outcome
Subgroup 3 (beneﬁt-driven) Relative risk ratio (RRR) 95% conﬁdence interval P-value
Age 0.99 0.96–1.03 0.73
Employment status (paid/unpaid)a 1.34 0.58–3.12 0.49
Educational level
Moderate 6.08 0.71–51.8 0.10
High 11.37 0.97–133.6 0.05**
Current bDMARD use (yes/no) 0.93 0.48–1.76 0.82
Complexity score online survey (1–10) 0.88 0.68–1.13 0.32
Educational level×complexity of the online survey
Moderate 0.77 0.53–1.12 0.17
High 0.80 0.53–1.18 0.26
Sum score necessity beliefs 1.12 1.00–1.23 0.055*
Constant 0.27 0.01–9.22 0.47
Notes: aThe student was assigned to the category of “unpaid” employment status. **Signiﬁcant contribution to the model (bold values); *Near-signiﬁcant contribution to the
model (bold value).
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